// STATE LEGISLATION TRACKER

New Jersey A3591: Requires NJ FamilyCare reimbursement for pediatric medication management services provided for certain children by licen

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: In committee

State: New Jersey
Bill: A3591
Session: 222
Filed: 2026-01-13
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

A3591 would require NJ FamilyCare to reimburse licensed clinical pharmacists for comprehensive medication management services for medically complex pediatric patients. Based on the title, subjects, and available bill text, it does not address compounded peptides, off-label peptide prescribing, telehealth, NP or naturopath scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No direct change to peptide access or prescribing rules
Applies to certain pediatric NJ FamilyCare patients
Creates reimbursement for pharmacist medication reviews
Does not appear to regulate compounding pharmacies
Does not expand NP, naturopath, or telehealth peptide practice

What to Watch For

Note Watch for amendments that broaden the bill beyond pediatric Medicaid medication management.

Note Pharmacist review authority could matter indirectly if future language covers specialty or compounded drugs.

Note No current signal that this bill changes controlled substance or prescription monitoring rules.

Where the Bill Stands

The bill was introduced and referred to the Assembly Health Committee, where it has not yet passed out for a floor vote.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws